Datapoint: Mirati Scores KRAS Nod for Krazati

The FDA on Dec. 12 granted an accelerated approval to Mirati Therapeutics’ Krazati for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients that have received at least one other systemic therapy. The KRAS inhibitor, Mirati’s first commercial product, will face off against Amgen’s blockbuster-hopeful Lumakras, which gained approval in May 2021. Lumakras was the first KRAS inhibitor on the market, and currently holds covered or better status for 94% of all insured lives under the pharmacy benefit for the treatment of KRAS-mutated NSCLC. About 15.5% of covered lives have preferred access to Lumakras.

SOURCE: MMIT Analytics, as of 12/14/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today